OBJECTIVE: The objective of this study was to compare diagnostic yield and complication rate in needle biopsy (NB) of renal hilar and cortical masses. MATERIALS AND METHODS: With institutional review board approval, we retrospectively studied 195 patients (120 men, 75 women; mean age ± SD, 67 ± 13 years old) who underwent ultrasound-guided renal mass NB between January 2013 and December 2017. Operator years of experience, biopsy technique (coaxial or successive), needle gauge (22-gauge fine-needle aspiration, 18-gauge core-needle, or both), number of passes, postprocedural complication, and histopathologic diagnoses were recorded. A radiologist who was blinded to histopathologic diagnoses recorded mass location (upper pole, interpolar region, lower pole) and percentage of hilar involvement. Comparisons were performed using independent t and chi-square tests. RESULTS: Of the masses biopsied, 5.6% (11/195) were 100% hilar (mean hilar involvement, 20.8% ± 29.8%; range, 0-100%). Mean lesion size was 44 ± 27 mm (range, 12-157 mm). NB diagnosis was established in 84.6% (165/195) of masses, and 15.4% (30/195) of biopsies were inconclusive, with no association with size (p = 0.55) or percentage of hilar involvement (p = 0.756). In the purely hilar masses, diagnosis was established in 72.7% (8/11) compared with 85.3% (157/184) with any cortical involvement (p = 0.265). There was no association between diagnosis and operator years of experience, biopsy technique, needle gauge, or number of passes (p > 0.05). Bleeding occurred after biopsy in 7.7% (15/195) of cases, was associated with percentage of hilar involvement (39.3% ± 44.9% vs 19.3% ± 27.8%; p = 0.012), and was more common in purely hilar masses (36.4% [4/11] vs 5.6% [11/195]; p < 0.001). Complications were not associated with any other feature (p > 0.05). CONCLUSION: Percutaneous biopsy of renal hilar masses is technically feasible with diagnostic yield similar to that of cortical masses but with postprocedural bleeding more often than what is seen with cortical masses.
OBJECTIVE: The objective of this study was to compare diagnostic yield and complication rate in needle biopsy (NB) of renal hilar and cortical masses. MATERIALS AND METHODS: With institutional review board approval, we retrospectively studied 195 patients (120 men, 75 women; mean age ± SD, 67 ± 13 years old) who underwent ultrasound-guided renal mass NB between January 2013 and December 2017. Operator years of experience, biopsy technique (coaxial or successive), needle gauge (22-gauge fine-needle aspiration, 18-gauge core-needle, or both), number of passes, postprocedural complication, and histopathologic diagnoses were recorded. A radiologist who was blinded to histopathologic diagnoses recorded mass location (upper pole, interpolar region, lower pole) and percentage of hilar involvement. Comparisons were performed using independent t and chi-square tests. RESULTS: Of the masses biopsied, 5.6% (11/195) were 100% hilar (mean hilar involvement, 20.8% ± 29.8%; range, 0-100%). Mean lesion size was 44 ± 27 mm (range, 12-157 mm). NB diagnosis was established in 84.6% (165/195) of masses, and 15.4% (30/195) of biopsies were inconclusive, with no association with size (p = 0.55) or percentage of hilar involvement (p = 0.756). In the purely hilar masses, diagnosis was established in 72.7% (8/11) compared with 85.3% (157/184) with any cortical involvement (p = 0.265). There was no association between diagnosis and operator years of experience, biopsy technique, needle gauge, or number of passes (p > 0.05). Bleeding occurred after biopsy in 7.7% (15/195) of cases, was associated with percentage of hilar involvement (39.3% ± 44.9% vs 19.3% ± 27.8%; p = 0.012), and was more common in purely hilar masses (36.4% [4/11] vs 5.6% [11/195]; p < 0.001). Complications were not associated with any other feature (p > 0.05). CONCLUSION: Percutaneous biopsy of renal hilar masses is technically feasible with diagnostic yield similar to that of cortical masses but with postprocedural bleeding more often than what is seen with cortical masses.
Authors: Brett A Johnson; Sandy Kim; Ryan L Steinberg; Alberto Diaz de Leon; Ivan Pedrosa; Jeffrey A Cadeddu Journal: Urol Oncol Date: 2019-09-17 Impact factor: 3.498